Edition:
United Kingdom

SCYNEXIS Inc (SCYX.OQ)

SCYX.OQ on NASDAQ Stock Exchange Global Market

1.16USD
14 Jun 2019
Change (% chg)

$0.01 (+0.87%)
Prev Close
$1.15
Open
$1.15
Day's High
$1.17
Day's Low
$1.13
Volume
33,327
Avg. Vol
107,475
52-wk High
$2.14
52-wk Low
$0.36

Latest Key Developments (Source: Significant Developments)

Scynexis Q1 Loss Per Share $0.46
Wednesday, 8 May 2019 

May 8 (Reuters) - SCYNEXIS Inc ::SCYNEXIS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q1 LOSS PER SHARE $0.46.Q1 EARNINGS PER SHARE ESTIMATE $-0.20 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $39.1 MILLION AS OF MARCH 31, 2019.  Full Article

SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study,
Wednesday, 3 Apr 2019 

April 3 (Reuters) - SCYNEXIS Inc ::SCYNEXIS'S IBREXAFUNGERP SHOWS FAVORABLE CLINICAL ACTIVITY IN RESISTANT FUNGAL INFECTIONS, INCLUDING CANDIDA AURIS CASES FROM THE CARES STUDY, IN DATA TO BE PRESENTED AT THE 29TH ECCMID.SCYNEXIS INC - IBREXAFUNGERP SHOWS STRONG CLINICAL ACTIVITY IN DIFFICULT-TO-TREAT PATIENTS WITH RESISTANT CANDIDA PATHOGENS.SCYNEXIS INC - SIX PRESENTATIONS WILL PROVIDE ADDITIONAL EVIDENCE OF POTENT AND BROAD ANTIFUNGAL ACTIVITY OF ORAL IBREXAFUNGERP.SCYNEXIS INC - SCYNEXIS'S IBREXAFUNGERP SHOWS FAVORABLE CLINICAL ACTIVITY IN RESISTANT FUNGAL INFECTIONS.  Full Article

Scynexis Announces FDA Agreement With Company-Proposed Phase 3 Vulvovaginal Candidiasis Program For Oral Ibrexafungerp
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - SCYNEXIS Inc ::SCYNEXIS ANNOUNCES FDA AGREEMENT WITH COMPANY-PROPOSED PHASE 3 VULVOVAGINAL CANDIDIASIS PROGRAM FOR ORAL IBREXAFUNGERP.SCYNEXIS INC - ON TARGET TO INITIATE PHASE 3 REGISTRATION PROGRAM IN Q4 OF 2018.SCYNEXIS INC - PLAN TO FILE A NEW DRUG APPLICATION (NDA) FOR TREATMENT OF VVC IN 2020.  Full Article

Scynexis Provides Corporate And SCY-078 Pipeline Update
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Scynexis Inc ::SCYNEXIS PROVIDES CORPORATE AND SCY-078 PIPELINE UPDATE.SCYNEXIS INC - ‍INTENDS TO INITIATE A PHASE 1 STUDY IN HEALTHY VOLUNTEERS IN Q3 2018, PENDING FDA'S REVIEW FOR LIPOSOMAL IV FORMULATION OF SCY-078​.SCYNEXIS INC - ‍PLANS TO INITIATE A PHASE 2B STUDY OF SCY-078 IN INVASIVE CANDIDIASIS WITH LIPOSOMAL IV FORMULATION IN Q4 OF 2018​.SCYNEXIS - ‍ANTICIPATES DOSE REGIMEN SELECTED FROM DOVE STUDY TO BE SUBSEQUENTLY EVALUATED IN PHASE 3 STUDIES FOLLOWING END-OF-PHASE 2 MEETING WITH FDA​.  Full Article

Scynexis reports third quarter 2017 financial results
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Scynexis Inc :Scynexis reports third quarter 2017 financial results and provides company update.Q3 loss per share $0.31.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.  Full Article